advocacy

First Opinion By Hil Moss

Enough pink: We’re doing Breast Cancer Awareness Month all wrong

Politics By Rachel Cohrs

Big business lobbies bitterly divided over drug pricing reform

Politics By Nicholas Florko and Rachel Cohrs

‘A solid black eye’: Drug pricing reform advocates scramble to reset after setback in Congress

Opinions+ By Monique K. Mansoura

A 10-point plan for sustaining the biopharma industrial base for a more secure nation

First Opinion Podcast By Patrick Skerrett

Listen: A father describes the legacy of his son’s ultra-rare disease

First Opinion By Matthew J. Meyer

Doctors pledge to do no harm. The entire health care sector should do the same by battling climate change

First Opinion By William Cooke

Harm-reduction programs acknowledge the difference between ‘do no harm’ and ‘protect from harm’

Politics By Lev Facher

Billions in new research funding sparks a lobbying frenzy among patient advocates

First Opinion Podcast By Patrick Skerrett

Listen: A longtime glioblastoma survivor on how to keep surviving

First Opinion By Adam Hayden

‘Here be dragons’: Long-term survivors like me can help map the boundaries of cancer

First Opinion By Ethan Dmitrovsky

A close brush with gun violence made me think about how to confront an epidemic during a pandemic

Politics By Rachel Cohrs

Hospitals and pharma are both on the hook to help fund infrastructure deal

First Opinion By Steve Cohen

On menthol cigarettes, social justice theory shouldn’t trump science

First Opinion By Winnie Byanyima and Chip Lyons

A turning point for children: creating an AIDS-free generation

First Opinion By Michael S. Sinha and Stephen Latham

Patient advocacy organizations and FDA drug approval: lessons from Aduhelm

First Opinion By Leslie Boden, Will Raderman and Patricia Fabian

Circumventing Covid-19 with better ventilation and air quality

Politics By Rachel Cohrs

Pharma CEOs, lobbyists showered Democrat with cash after his attempt to torpedo Pelosi’s drug pricing bill

First Opinion By Margaret Goldberg

Patient advocacy groups and innovators must partner to advance new treatments

Politics By Nicholas Florko

Is the Alzheimer’s Association really pushing Biogen to lower its new drug’s price — or is it lip service?

First Opinion By Kollet Koulianos and Keri Norris

Copay assistance should count as part of patients’ cost sharing for medications

D.C. Diagnosis By Nicholas Florko

Operation Warp Speed — now, the ‘CAG’— is here to stay

First Opinion By David Introcaso and Walt Vernon

Public reporting: the first step in addressing the health care industry’s bloated carbon footprint

First Opinion By Lipi Roy, Reshma Gupta and Bhavna Lall

India’s doctors — at home and abroad — face Covid’s unrelenting toll

Politics By Nicholas Florko

Bipartisan pair of senators calls on Congress to examine expensive new Alzheimer’s drug 

D.C. Diagnosis By Rachel Cohrs

The lonely quest to create a commission to investigate Covid-19